Ever undergone reconstructive orthopedic surgery? Yes, then you may have been implanted with one of the personalized joint replacement technologies of Indiana-based, one of the leading orthopedic medical devices manufacturer–Zimmer Biomet Holdings, Inc. (NYSE:ZBH) , formerly known as Zimmer Holdings. In June 2015, legacy Zimmer completed the acquisition of Biomet for $14.0 billion. With operations in more than 25 countries, the company markets its orthopedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products in more than 100 countries.
Currently, Zimmer Biomet has a Zacks Rank #4 (Sell) but that could change following its fourth quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate stands at $2.10 per share over the last 60 days. Zimmer Biomet’s adjusted earnings per share of $2.10, in line with the Zacks Consensus Estimate.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Zimmer Biomet Holdings, Inc. Price and EPS Surprise | Zimmer Biomet Holdings, Inc. Quote
Revenues: Zimmer Biomet posted revenues of $2.07 billion which has surpassed the Zacks Consensus Estimate for revenues of $2.03 billion.
Key Stats: Fourth-quarter revenues derived from Zimmer’s Knees segment were increased 1.4% year over year to $731.2 million, while Hips recorded sales of $499.1 million, up 3.5% compared with the prior-year quarter. Revenues from S.E.T (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) improved 5.9% year over year to $454.6 million.
Major Factors: The year-over-year revenue growth in all business segments buoys optimism. The company witnessed strong Asia-Pacific performance at constant exchange rate. The company also issued its first quarter 2018 sales and earnings guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Zimmer Biomet earnings report later!
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks’ has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
Original post